Shares Magazine
7.75p+0.00 (+0.00%)22 Nov 2024, 16:37
Jump to:
Renalytix PLC Fundamentals
| Company Name | Renalytix PLC | Last Updated | 2024-11-22 |
|---|---|---|---|
| Industry | Health Information Services | Sector | Healthcare |
| Shares in Issue | 333.638 m | Market Cap | £25.86 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -$0.31 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 1.7215 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | -0.4235 | Cash Equity Ratio | -0.0803 |
| Quick Ratio | 0.1508 | Current Ratio | 0.24 |
| Price To Book Value | 0 | ROCE | 0 |
Renalytix PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Renalytix PLC Company Financials
| Assets | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tangible Assets | $216,000.00 | $1.19 m | $1.37 m | $2.46 m |
| Intangible Assets | 0 | 0 | 0 | $18.02 m |
| Investments | $698,000.00 | $1.46 m | $2.75 m | 0 |
| Total Fixed Assets | $1.85 m | $3.75 m | $5.31 m | $26.57 m |
| Stocks | 0 | 0 | 0 | $353,000.00 |
| Debtors | $722,000.00 | $776,000.00 | $976,000.00 | $594,000.00 |
| Cash & Equivalents | $4.68 m | $24.68 m | $41.33 m | $74.45 m |
| Other Assets | 0 | 0 | 0 | $6.09 m |
| Total Assets | $7.97 m | $30.63 m | $50.06 m | $102.58 m |
| Liabilities | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Creditors within 1 year | $11.49 m | $16.14 m | $11.78 m | $7.26 m |
| Creditors after 1 year | $4.33 m | $7.53 m | $7.68 m | $213,000.00 |
| Other Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | $15.83 m | $23.66 m | $19.46 m | $7.48 m |
| Net assets | -$7.85 m | $6.97 m | $30.61 m | $95.10 m |
| Equity | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Called up share capital | $478,000.00 | $286,000.00 | $228,000.00 | $233,000.00 |
| Share Premium | $204.89 m | $186.46 m | $164.01 m | $76.46 m |
| Profit / Loss | -$33.45 m | -$45.60 m | -$45.25 m | -$35.79 m |
| Other Equity | -$7.85 m | $6.97 m | $30.61 m | $95.10 m |
| Preference & Minorities | 0 | 0 | 0 | 0 |
| Total Capital Employed | -$7.85 m | $6.97 m | $30.61 m | $95.10 m |
| Ratios | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Debt Ratio | 0 | $0.52 | $0.20 | $0.00 |
| Debt-to-Equity | 0 | $1.08 | $0.25 | $0.00 |
| Assets / Equity | -0.4235 | -0.4235 | -0.4235 | -0.4235 |
| Cash / Equity | -0.0803 | -0.0803 | -0.0803 | -0.0803 |
| EPS | -$0.26 | -$0.50 | -$0.60 | -$0.51 |
| Cash Flow | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash from operating activities | -$30.11 m | -$34.09 m | -$45.92 m | -$24.63 m |
| Cashflow before financing | -$19.86 m | -$17.70 m | -$20.29 m | $52.61 m |
| Increase in Cash | -$20.00 m | -$16.65 m | -$23.80 m | $51.87 m |
| Income | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Turnover | $2.29 m | $3.40 m | $2.97 m | $1.49 m |
| Cost of sales | $2.13 m | $2.68 m | $2.10 m | $804,000.00 |
| Gross Profit | $156,000.00 | $720,000.00 | $874,000.00 | $687,000.00 |
| Operating Profit | -$29.61 m | -$42.22 m | -$53.18 m | -$32.61 m |
| Pre-Tax profit | -$33.45 m | -$45.60 m | -$45.25 m | -$35.79 m |
Renalytix PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. |
| Latest Interim Date | 15 Feb 2024 |
| Latest Fiscal Year End Date | 1 Oct 2024 |
Renalytix PLC Directors
| Appointed | Name | Position |
|---|---|---|
| Invalid DateTime | Ms. Ann E. Berman | Independent Director |
| 2023-11-20 | Mr. Howard B. Doran, Jr. | Chief Business Officer |
| 2024-06-11 | Mr. Joel R. Jung | Interim Chief Financial Office |
| 2023-07-10 | Mr. Thomas H. Mclain | President |
| Invalid DateTime | Mr. Timothy John Scannell | Independent Director |
| Invalid DateTime | Mr. Daniel Joseph Levangie | Non-Executive Director |
| Invalid DateTime | Mr. Christopher Harwood Bernard Mills | Non-Executive Director |
| Invalid DateTime | Mr. Julian Huw Baines MBE | Executive Director,Chairman |
| Invalid DateTime | Mr. Richard Anthony Evans | Non-Executive Director |
| Invalid DateTime | Mr. James Renwick McCullough | Executive Director,Chief Executive Officer |
| Invalid DateTime | Mr. Fergus Fleming | Executive Director,Chief Technical Officer |
| Invalid DateTime | Dr. Barbara Murphy | Independent Director |
| 2023-07-01 | Dr. Erik Lium, PhD | Director |
| Invalid DateTime | Mr. O. James Sterling | Chief Financial Officer and Principal Accounting Officer |
| Invalid DateTime | Dr. Chirag Rohit Parikh, M.D.,PhD | Independent Director |
| 2023-07-06 | Dr. Michael J. Donovan, M.D.,PhD | Chief Medical Officer |
| Invalid DateTime | Ms. Catherine Havlik Coste, C.P.A. | Non-Executive Director |
Renalytix PLC Contact Details
| Company Name | Renalytix PLC |
|---|---|
| Address | 19 Stanwell Road, Avon House, Cardiff, CF64 2EZ |
| Telephone | |
| Website | https://www.renalytix.com |
Renalytix PLC Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
